Singapore’s biotech strategy will benefit from collective, not competitive, thinking
Successful innovation requires a holistic risk-based approach beyond financial, infrastructure and manpower investments
Add BT as a preferred source
IN AN interview with private-equity investor David Rubenstein, chief executive officer of Novartis Dr Vasant Narasimhan spoke about the potential and possibilities of pharmaceuticals in a fiercely competitive industry.
Rubenstein questioned Dr Narasimhan on whether constant drug patent expiry and the need to generate new portfolio of drugs is a good way to make a business. Dr Narasimhan acknowledged the “constant treadmill” and the value of a company’s replacement power, which requires strong research and development capabilities, as well as long-term thinking.
Few industries in the world are subject to such clockwork-style competitive advantage erosion, where businesses know the exact year in which generic drug sales will erode their revenues.
TRENDING NOW
Father-and-son duo Raj Kumar and Kishin in exclusive due diligence to buy Scotts Square
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Koh Brothers Eco Engineering faces up to S$57.6 million in potential legal liabilities
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
